Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of ...

VTEX (NYSE: VTEX), the backbone for connected commerce, today announced results for the fourth quarter and fiscal year 2025 ended December 31, 2025. VTEX results have been prepared in accordance with ...

NuScale’s exclusive global strategic partner, ENTRA1 Energy (“ENTRA1”), and Tennessee Valley Authority (“TVA”) continue to advance the largest nuclear power deployment program in U.S. history NuScale ...

Good day, everyone, and welcome to the Charles River Associates Fourth Quarter 2025 Conference Call. Please note that today's call is being recorded. The company's earnings release and prepared ...

Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) (“Orbia” or “the Company”) announced today that James P. “Jim” Kelly ...

Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax approved by the U.S. FDA for the treatment of locally advanced pancreatic cancer, commercial ...

All financial figures are in Canadian dollars unless otherwise noted. This news release refers to certain financial measures ...